However, we need to be cautious about comparing these percentages, not only with phentolamine but across all currently marketed presbyopia drops. The pivotal trials were conducted in different patient populations and under different protocols, so cross-trial comparisons do not support direct efficacy rankings.
What stands out to me about phentolamine, assuming the labeled claim holds, is not the size of the near-vision gain but how it gets there. The distinction matters because “non-ciliary” differentiates it from some competitors but not others. Pilocarpine contracts both the iris sphincter and the ciliary muscle, which is why it can produce accommodative brow-ache and a myopic shift. Yuvezzi likewise engages the ciliary apparatus: its carbachol component is a cholinergic agonist that constricts the iris sphincter and ciliary body, while the brimonidine component relaxes the iris dilator and tonic ciliary contraction to sharpen pupil selectivity and prolong the carbachol effect. Aceclidine is actually the exception among the miotics; its label describes it as a predominantly pupil-selective agent that contracts the iris sphincter with minimal ciliary muscle stimulation. Aceclidine also already spares the ciliary muscle. What makes phentolamine unique is the route it takes to the pupil: it is the only one of these agents that produces miosis purely sympatholytically, by alpha-blockade relaxing the iris dilator with no cholinergic action on the sphincter or ciliary body at all. Pair that with evening dosing and you have a genuinely distinct pharmacologic profile. This mechanism was seen early in the phase 2b ORION-1 study, in which an evening dose produced a sustained pupil reduction and a near-vision gain that hung on for well over a day.6
It is important to recognize that no drops restore the eye’s natural accommodative ability. They all borrow the pinhole effect to deepen depth of focus. The real question for me is never the peak responder rate, it is tolerability and duration, because those are what decide whether a patient is still using the drop 6 months later.
Phentolamine reduces pupil size by blocking the iris dilator muscle rather than stimulating the ciliary muscle, as miotic drops do. How might this difference, along with once-daily evening dosing, affect patient selection, tolerability, and adherence?
Epitropoulos: For me, the mechanism is the most interesting part of the story. Phentolamine is a non-selective alpha-1/alpha-2 blocker that shrinks the pupil by relaxing the iris dilator rather than contracting the sphincter or the ciliary body.
That is a genuinely different route to depth of focus, and it distinguishes phentolamine from pilocarpine and the other muscarinic agents, ciliary and sphincter activity of which drives the three complaints that limit the tolerability of daytime drops: the brow-ache and headache of accommodative spasm, myopic shift and blur, and dim vision that makes patients nervous about driving at night. Because phentolamine never engages the ciliary muscle, I would expect it to sidestep most of that, and in practice that matters most for the patient who wants a pharmacologic option but cannot tolerate or does not want the accommodative effects of a cholinergic miotic.
The bedtime, once-daily schedule is the other piece I like. Rather than remembering a drop in the morning and maybe a second dose during the workday, the idea is to dose in the evening and have the near-vision benefit ready the next day. That decouples the medicine from the very dimming and brow-ache that drive patients off daytime miotics, and once a day is simply easier to sustain. Both should help adherence, although real-world adherence will ultimately come down to how patients weigh the size of the benefit against any visual or surface symptoms. The ORION-1 durability data make an overnight-dosed, all-day effect plausible to me.6
That said, the trade-offs are different, not gone. I would not call phentolamine side effect-free. The reported effects are mostly local: instillation discomfort, conjunctival hyperemia, and a transient bad taste (dysgeusia), although in VEGA-3 the adverse events were predominantly mild and there were no treatment-related serious adverse events. Its sympatholytic mechanism makes systemic alpha-blockade worth a passing thought in patients already on oral alpha-blockers or prone to orthostasis, although this is not a labeled precaution, and systemic absorption from a topical drop is expected to be minimal. Because phentolamine produces miosis without contracting the ciliary muscle, it does not share the mechanistic pathway most often invoked for miotic-associated retinal detachment, and unlike the cholinergic presbyopia drops, its label carries no retinal-detachment precaution. That said, the retinal-detachment warning applied to the parasympathomimetics (pilocarpine, aceclidine, and the carbachol component of Yuvezzi) is the reason a dilated retinal examination is advised before starting those agents, consistent with American Academy of Ophthalmology guidance.7 Whether phentolamine's sympatholytic mechanism translates into a lower real-world detachment risk remains unproven.
Which patients are the best candidates for phentolamine, and how might it fit alongside or in combination with existing presbyopia options, including glasses, contact lenses, and other drops?
Epitropoulos: The ideal candidate is likely a motivated reader-reluctant, early-to-moderate presbyope, typically in their mid-40s to mid-50s, with good baseline distance vision and a meaningful need for better unaided near vision. This is someone who wants the freedom to read without reaching for readers at every opportunity and is open to a topical treatment but would prefer to avoid directly stimulating the ciliary muscle. I would also consider patients' pupil characteristics, ocular surface status, visual demands, and tolerance for potential changes in visual quality when deciding whether this approach is appropriate.
I do not see any of these drops replacing glasses or contacts. I frame them as an adjunct and a lifestyle option, ie, a way to lean on readers less for intermediate and near work during the day, to complement a monovision or multifocal contact-lens plan, or to serve someone who just dislikes progressives. I would be more cautious in higher uncorrected hyperopes and advanced presbyopes, who will likely still need correction for fine print; in patients with meaningful dry eye or surface disease, where instillation discomfort and redness matter more.
Rather than expecting one universally superior product, I see these drops as potentially complementary options. Phentolamine's mechanism may make it particularly attractive for patients who want a non-miotic, non-accommodative approach.
The VEGA program also explored phentolamine in combination with low-dose pilocarpine, which raises an interesting possibility of tailoring the pharmacologic effect, although any combination should be guided by the eventual FDA labeling and clinical evidence rather than assuming that combination therapy is appropriate for routine practice.
The combination data actually came from the earlier VEGA-1 Ocuphire Pharma trial, where adding 0.4% pilocarpine to 0.75% phentolamine raised three-line responders to 60.5% from 45.2% but roughly doubled the adverse events, to 34.1% from 19.4%, a clear illustration of the efficacy-versus-tolerability trade-off that any combination approach has to weigh.
References
Opus Genetics announces VEGA-3 phase 3 trial met its primary end point for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. News release. Opus Genetics. Accessed November 17, 2026. https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia.
Lima GN, Amaral DC, Ivanov YA, et al. Short-term efficacy and safety of pilocarpine ophthalmic solution for presbyopia: a systematic review and meta-analysis. Am J Ophthalmol. 2025;279:52-9. doi: 10.1016/j.ajo.2025.08.033
Holland E, Karpecki P, Fingeret M, et al. Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials. Clinical Therapeutics. 2024;46:50-59. doi:10.1016/j.clinthera.2023.12.005
CLARITY-1 (LNZ100/aceclidine in presbyopia). ClinicalTrials.gov. Updated May 13, 2026. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT05656027
CLARITY-2 (LNZ100/aceclidine in presbyopia). ClinicalTrials.gov. Updated October 29, 2026. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT05728944
Pepose JS, Hartman PJ, DuBiner B, et al. Phentolamine mesylate ophthalmic solution provides lasting pupil modulation and improves near visual acuity in presbyopic glaucoma patients in a randomized Phase 2b clinical trial (ORION-1). Clin Ophthalmol. 2021;15:225–36. doi: 10.2147/OPTH.S278169
Jacobs DS, Afshari NA, Bishop RJ, et al. American Academy of Ophthalmology Preferred Practice Pattern Refractive Management/Intervention Panel. Refractive errors preferred practice pattern. Ophthalmology. 2023;130:P1-P60. doi:10.1016/j.ophtha.2022.10.031